Peptide-Fatty Acid Conjugates for PTHR1 Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypoparathyroidism require frequent injections of PTH(1-34) due to short pharmacokinetic and pharmacodynamic properties, and there is a need for PTHR1 agonists, antagonists, and inverse agonists with high affinity and prolonged action that are easy to synthesize and purify.
Innovation Solution
Development of conjugates comprising a PTHR1 agonist, antagonist, or inverse agonist peptide linked with a fatty acid acyl through a specific linker, which can be covalently attached to the peptide, enhancing pharmacokinetic properties and reducing clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PTH(1-34) is used to treat hypoparathyroidism, then serum calcium levels can be maintained, but frequent injections are required due to short pharmacokinetic properties
Solution Approach 1:
The patent creates composite molecules by conjugating PTH(1-34) peptide with fatty acid moieties (such as palmitic acid) through linkers. This composite structure combines the calcium-regulating activity of PTH with the prolonged circulation properties of fatty acid-albumin complexes, extending the pharmacokinetic duration from hours to days while maintaining therapeutic effectiveness.
2Reliability
If PTH(1-34) is administered frequently, then effective serum calcium levels are maintained, but patient compliance and convenience deteriorate
Solution Approach 1:
The fatty acid conjugated PTH molecules spontaneously bind to serum albumin in the bloodstream, creating a self-sustaining circulation system. The albumin-PTH conjugate complex is naturally protected from rapid clearance, allowing the therapeutic agent to maintain effective levels in the body for extended periods without requiring frequent re-administration.
3Duration of action of moving object
If PTH analogs with prolonged action are developed, then administration frequency can be reduced, but synthesis and purification complexity increases
Solution Approach 1:
The PTH molecule is modified at specific sites (such as N-terminal or side-chain amino groups) while leaving the core calcium-regulating sequence intact. This segmented approach allows the fatty acid conjugation to occur at peripheral positions, minimizing interference with the peptide's biological activity and simplifying purification by targeting the unique fatty acid moiety.
Data Source
AI summary
Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, or thrombocytopenia).